| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| S R Laviolette, A A Grac. The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. Cellular and molecular life sciences : CMLS. vol 63. issue 14. 2006-09-19. PMID:16699809. |
this review describes evidence for functional neural interactions between cannabinoid and da receptor systems and how disturbances in this neural circuitry may underlie the aberrant emotional learning and processing observed in disorders such as addiction and schizophrenia. |
2006-09-19 |
2023-08-12 |
Not clear |
| Suresh Sundra. Cannabis and neurodevelopment: implications for psychiatric disorders. Human psychopharmacology. vol 21. issue 4. 2006-08-31. PMID:16783814. |
the effect of cannabinoids in the adolescent suggest long-term deleterious outcomes in cognition, depressive symptoms, schizophrenia and substance use disorders. |
2006-08-31 |
2023-08-12 |
human |
| Sharon Monterrubio, Nadia Solowij, Barbara J Meyer, Nigel Turne. Fatty acid relationships in former cannabis users with schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 30. issue 2. 2006-06-08. PMID:16236415. |
abnormalities in the fatty acid (fa)-based endocannabinoid lipid signaller anandamide, and prevalent cannabis use, have been found to be associated with schizophrenia and may potentially alter stress mechanisms. |
2006-06-08 |
2023-08-12 |
Not clear |
| N Ballon, S Leroy, C Roy, M C Bourdel, A Charles-Nicolas, M O Krebs, M F Poirie. (AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population. The pharmacogenomics journal. vol 6. issue 2. 2006-04-28. PMID:16314880. |
owing to their agonist action on dopaminergic systems, cannabinoids may play a major role in substance dependency and schizophrenia. |
2006-04-28 |
2023-08-12 |
human |
| Mark Weiser, Shlomo No. Interpreting the association between cannabis use and increased risk for schizophrenia. Dialogues in clinical neuroscience. vol 7. issue 1. 2006-01-13. PMID:16060598. |
recent investigations of patients with schizophrenia found increased density of cannabinoid receptors in the dorso-lateral prefrontal cortex and the anterior cingulate cortex. |
2006-01-13 |
2023-08-12 |
Not clear |
| J Haller, M Szirmai, B Varga, C Ledent, T F Freun. Cannabinoid CB1 receptor dependent effects of the NMDA antagonist phencyclidine in the social withdrawal model of schizophrenia. Behavioural pharmacology. vol 16. issue 5-6. 2006-01-09. PMID:16148446. |
cannabinoid cb1 receptor dependent effects of the nmda antagonist phencyclidine in the social withdrawal model of schizophrenia. |
2006-01-09 |
2023-08-12 |
mouse |
| J Haller, M Szirmai, B Varga, C Ledent, T F Freun. Cannabinoid CB1 receptor dependent effects of the NMDA antagonist phencyclidine in the social withdrawal model of schizophrenia. Behavioural pharmacology. vol 16. issue 5-6. 2006-01-09. PMID:16148446. |
clinical and laboratory findings suggest that cannabinoid signalling is implicated in schizophrenia. |
2006-01-09 |
2023-08-12 |
mouse |
| J Haller, M Szirmai, B Varga, C Ledent, T F Freun. Cannabinoid CB1 receptor dependent effects of the NMDA antagonist phencyclidine in the social withdrawal model of schizophrenia. Behavioural pharmacology. vol 16. issue 5-6. 2006-01-09. PMID:16148446. |
here we investigated wild-type (wt) and cannabinoid cb1 receptor-knockout (cb1-ko) mice in the phencyclidine-induced social withdrawal model of schizophrenia. |
2006-01-09 |
2023-08-12 |
mouse |
| Yukitaka Morita, Hiroshi Ujike, Yuji Tanaka, Naohiko Uchida, Akira Nomura, Kyohei Ohtani, Makiko Kishimoto, Akiko Morio, Takaki Imamura, Ayumu Sakai, Toshiya Inada, Mutsuo Harano, Tokutaro Komiyama, Mitsuhiko Yamada, Yoshimoto Sekine, Nakao Iwata, Masaomi Iyo, Ichiro Sora, Norio Ozaki, Shigetoshi Kurod. A nonsynonymous polymorphism in the human fatty acid amide hydrolase gene did not associate with either methamphetamine dependence or schizophrenia. Neuroscience letters. vol 376. issue 3. 2005-05-26. PMID:15721218. |
because the pro129thr polymorphism reduces enzyme instability, it is unlikely that dysfunction of faah and enhanced endocannabinoid system induce susceptibility to either methamphetamine dependence/psychosis or schizophrenia. |
2005-05-26 |
2023-08-12 |
human |
| Hiroshi Ujike, Yukitaka Morit. New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. Journal of pharmacological sciences. vol 96. issue 4. 2005-04-28. PMID:15613777. |
new perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. |
2005-04-28 |
2023-08-12 |
Not clear |
| Hiroshi Ujike, Yukitaka Morit. New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. Journal of pharmacological sciences. vol 96. issue 4. 2005-04-28. PMID:15613777. |
recent studies provide additional biological and genetic evidence for the cannabinoid hypothesis of schizophrenia. |
2005-04-28 |
2023-08-12 |
Not clear |
| Hiroshi Ujike, Yukitaka Morit. New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. Journal of pharmacological sciences. vol 96. issue 4. 2005-04-28. PMID:15613777. |
anandamide, an endogenous cannabinoid, is also increased in the csf in schizophrenia. |
2005-04-28 |
2023-08-12 |
Not clear |
| F Markus Leweke, Christoph W Gerth, Joachim Klosterkötte. Cannabis-associated psychosis: current status of research. CNS drugs. vol 18. issue 13. 2005-02-04. PMID:15521792. |
interestingly, the recently suggested role of the endogenous cannabinoid system in schizophrenia not related to previous cannabinoid consumption introduces an additional perspective on the mechanism underlying cannabis-associated schizophrenia-like disorders, as well as on the effects of cannabis consumption in schizophrenia. |
2005-02-04 |
2023-08-12 |
Not clear |
| Katerina Zavitsanou, Therese Garrick, Xu Feng Huan. Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 28. issue 2. 2004-05-28. PMID:14751433. |
selective antagonist [3h]sr141716a binding to cannabinoid cb1 receptors is increased in the anterior cingulate cortex in schizophrenia. |
2004-05-28 |
2023-08-12 |
human |
| Katerina Zavitsanou, Therese Garrick, Xu Feng Huan. Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 28. issue 2. 2004-05-28. PMID:14751433. |
this could suggest that changes in the cannabinoid (cb) system might be present in the acc of patients suffering schizophrenia. |
2004-05-28 |
2023-08-12 |
human |
| Katerina Zavitsanou, Therese Garrick, Xu Feng Huan. Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 28. issue 2. 2004-05-28. PMID:14751433. |
the present study examined the distribution and density of cb1 cannabinoid receptors in the left acc taken postmortem from patients with schizophrenia (n=10) and matched control subjects (n=9). |
2004-05-28 |
2023-08-12 |
human |
| Miriam Schneider, Michael Koc. Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 28. issue 10. 2003-12-05. PMID:12888772. |
since ppi deficits, object recognition memory impairments, and anhedonia/avolition are among the endophenotypes of schizophrenia, we propose chronic cannabinoid administration during pubertal development as an animal model for some aspects of the etiology of schizophrenia. |
2003-12-05 |
2023-08-12 |
rat |
| P D Skosnik, L Spatz-Glenn, S Par. Cannabis use is associated with schizotypy and attentional disinhibition. Schizophrenia research. vol 48. issue 1. 2001-05-31. PMID:11278156. |
these results suggest that cannabis use can mimic attentional deficits seen in acute schizophrenia and is associated with schizotypal personality, thus setting the stage for a possible cannabinoid model of sz. |
2001-05-31 |
2023-08-12 |
Not clear |
| S R Pryo. Is platelet release of 2-arachidonoyl-glycerol a mediator of cognitive deficits? An endocannabinoid theory of schizophrenia and arousal. Medical hypotheses. vol 55. issue 6. 2001-01-25. PMID:11090297. |
an endocannabinoid theory of schizophrenia and arousal. |
2001-01-25 |
2023-08-12 |
Not clear |
| F M Leweke, A Giuffrida, U Wurster, H M Emrich, D Piomell. Elevated endogenous cannabinoids in schizophrenia. Neuroreport. vol 10. issue 8. 1999-11-15. PMID:10501554. |
elevated endogenous cannabinoids in schizophrenia. |
1999-11-15 |
2023-08-12 |
Not clear |